Expedition Therapeutics
San Francisco
About Expedition Therapeutics
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases. The company advances EXPD-101, an oral once-daily inhibitor of DPP1, which targets neutrophilic inflammation and is positioned for chronic obstructive pulmonary disease (COPD) and other neutrophil-driven indications. It pursues global clinical development of EXPD-101 while exploring expansion into bronchiectasis, neutrophilic asthma, and related conditions. The leadership team combines expertise in drug discovery, translational science, clinical development, and business strategy. Expedition Therapeutics operates a model that integrates in-licensing of external innovation with internally generated programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $165.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2025)
- Website: expeditiontx.com
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/expedition-therapeutics-14708 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.